First, last, corresponding authors

This is a list of 2025 publications with cancer center members as either first, last, or corresponding author arranged by highest impact factor. University of Arizona Cancer Center members and associate authors are indicated in bold.

Chen, X, Shen, Y, Choi, S, Abdel-Hafiz HA, Basu M, Hoelzen L, & Theodorescu, D. Concurrent loss of the Y chromosome in cancer and T cells impacts outcome. Nature. 2025, June 4. Impact factor: 69.5

Scott AJ, Kennedy EB, Gholami S. Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer? J Clin Oncol. 2025, March 10. Impact factor: 44.5

Lu J, Wang Z, Li W, Jiang Y, Li M, Wu S, Ma T, Tran TB, Cordova LE, Lin E, Scott A, Erdrich, J, Schroeder, Chalasani, P, & Lu Jianqin. A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer. Nature Cancer. 2025, August 21. Impact factor: 23.5

Meng Y, Shu B, Zhang J, Rao H, Zhou Z, Wang Z, Liu Z, Liu K, Zhang Y, Wang W. Photocatalyst-free photochemical deuteration via H/D exchange with D₂O. Nat Commun. 2025, July 22. Impact factor: 17.694

Yang J, Lim JT, Santiago Raj PV, Corona MG, Chen C, Khawaja H, Pan Q, Paine-Murrieta GD, Schnellmann RG, Roe DJ, Gokhale PC, DeCaprio JA, Padi M. Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma. J Clin Invest. 2025, February 11. Impact factor: 14.8

Ebrahimi E, Naudin S, Dimou N, Mayen AL, Wang M, Abnet CC, Akesson A, Barnett MJ, Bellocco R, Berrington de Gonzalez A, Bonn SE, Chen C, Christiani DC, Crane TE, Eliassen AH, Freudenheim JL, Gao YT, Garcia-Closas M, Gierach G, Giovannucci EL, Gram IT, Hakansson N, Hirabayashi M, Hou T, Huang BZ, Huerta JM, Jayasekara H, Koh WP, Lacey JV, Lagerros YT, Loftfield E, MacInnis RJ, Mannisto S, Martinez ME, McCullough ML, Milne RL, Moore SC, Mucci LA, Neuhouser ML, Platz EA, Poynter JN, Prizment AE, Rees S, Robien K, Rohan TE, Sawada N, Setiawan VW, Shams-White MM, Shu XO, Sinha R, Stampfer MJ, Stolzenberg-Solomon RZ, Thomson CA, Um CY, van den Brandt PA, Visvanathan K, Wang R, Wang SS, White E, White KK, Willet WC, Wolk A, Yano Y, Yaun SS, Yuan JM, Zheng W, Riboli E, Smith-Warner SA, Brennan P, Ferrari P. Alcohol consumption and upper aerodigestive tract squamous cell carcinoma: evidence from 28 prospective cohorts. J Natl Cancer Inst. 2025, September 22. Impact factor: 13.506

Coronado G, Rutter C. Response to McElroy and Everett. J Natl Cancer Inst. 2025, June 1. Impact factor: 13.5

Mesgarzadeh S, Myrdal CN, Gong AH, Stratton DB, Kelly BG, Curiel-Lewandrowski C. Heterogeneity among melanoma databases and challenges in sustainability: A survey of the Melanoma Prevention Working Group. JAAD Int. 2025, Feb. 1. Impact factor: 12.8

Clements AN, Casillas AL, Flores CE, Liou H, Toth RK, Chauhan SS, Sutterby K, Deshmukh SK, Wu S, Xiu J, Farrell A, Radovich M, Nabhan C, Heath EI, McKay RR, Subah N, Centuori S,  Wheeler TJ, Cress AE, Rogers GC, Wilson JE, Recio-Boiles A, Warfel NA. Inhibition of PIM kinase in tumor-associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy. Cancer Immunol Res. 2025, May 2. Impact factor: 12

Chee D,  Ong CEY,  Tan DJ,  Schattenberg JM,  Ioannou GN,  Huang DQ,  Wijarnpreecha, K.  HCC Policy Study Group. Global health policies for hepatocellular carcinoma: a cross-sectional study. Clin Gastroenterol Hepatol. 2025, May 12. Impact factor: 11.3

Jiang Y, Wang Z, Li W, Ma T, Li M,  Wu S, Lin E, Flader KE, Ma M, Chang M, Li H, Wang W, Lu J. Enhanced Delivery of Camptothecin to Colorectal Carcinoma Using a Tumor-Penetrating Peptide Targeting p32. Acta Biomater. 2025, June 15. Impact factor: 10.6

Carew JS, Espitia CM, Sureshkumar S, Carrera Espinoza MJ, Gamble ME, Wang W, Lee BR, Nawrocki ST. REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity. Cancer Lett. 2025, March 2. Impact factor: 9.7

Basu M, Xiao JF, Kailasam Mani SK, Qu F, Lin Y, Duex J, Ye H, Neang V, Theodorescu D. Genes driving three-dimensional growth of immortalized cells and cancer. Cell Death Dis. 2025, June 10. Impact factor: 9.6

Jimenez NR, Herman CR, Łaniewski P, Cope E, Lee K, Mahnert ND, Chase DM, Caporaso JG, Herbst-Kralovetz MM. Navigating complexities of polymorphic microbiomes in endometrial cancer. npj Biofilms and Microbiomes. NJP. 2025, May 22. Impact factor: 9.2

Smith KA, Batatinha H, Niemiro GM, Baker FL, Zúñiga TM, Diak D, Mylabathula PL, Kistner TM, Davini D, Hoffman E, Colombo JN, Seckeler M, Bond RA, Katsanis E, Simpson RJ. Exercise-induced β(2)-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells. Brain Behav Immun. 2025, April 29. Impact factor: 8.8

Li M, Li W, Li Z, Lu J. Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines. Nano Res. 2025, July 18.  Impact factor: 8.7

Furlong MA, Liu T, Jung A, Beitel S, Hughes J, Krause R, Graber JM, Calkins MM, Calafat AM, Botelho JC, Huentelman M, Gulotta J, Goodrich JM, Burgess JL. Per- and polyfluoroalkyl Substances (PFAS) and microRNA: an epigenome-wide association study in firefighters. Environ Res. 2025; May 9. Impact factor: 8.4

Jimenez NR,  Herman CR,  Laniewski P, Cope E, Lee K, Mahnert ND, Chase DM, Caporaso JG, Herbst-Kralovetz MM. Navigating complexities of polymorphic microbiomes in endometrial cancer. NPJ. Biofilms Microbiomes. 2025, May 22. Impact factor: 8

Bernardazzi C, Saha T, Gurney MA, Laubitz D, Dey PD, Masannat T, Sheikh IA, Midura-Kiela MT, Ghishan FK, Kiela PR. NHE3 Controls Proliferation and Migration of Colonic Epithelial Cells. Inflamm Bowel Dis. 2025, February 17. Impact factor: 7.3

Keerthivasan MB, Toner B, Galons JP, Johnson K, Bilgin A, Martin DR, Altbach MI. Diagnosing abdominal neoplasms using a T2 mapping radial turbo spin-echo technique with partial volume correction. Eur Radiol. 2025, August 30. Impact factor: 7.034

Morenz A, Ganguly A, Kessler L, Coronado G. Asking About Cervical Cancer Screening in National Surveys: Implications for Health Literacy and Research. Am J Prev Med.  2025, July 1. Impact factor: 6.6

Kline I, Mokry RL, Xi Y, Passols Manzano M, Layesa S, Sohrab Ali N, Moy MA, Goodrum FD, Purdy JG. Human cytomegalovirus promotes de novo PC synthesis during early virus replication. bioRxiv. 2025, March 6. Impact factor: 6.549

Filioglou D, Santa-Cruz N, Leite GSF, Davini DW, Cracchiolo MJ, Baker FL, Husnain M, Simpson RJ, Voudouris V, Katsanis E. A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo. Cancers. 2025, May 14. Impact factor: 6.5

Mouneimne G,  Connors C,  Watson A,  Grant A,  Campo D,  Ring A,  Kaur P,  Lang JE. Mechanical Conditioning (MeCo) Score Progressively Increases Through the Metastatic Cascade in Breast Cancer via Circulating Tumor Cells. Cancers (Basel). 2025, May 12. Impact factor: 6.5

Schippel N, Kala M, Sharma S (CBP). Erythropoietin-dependent Acquisition of CD71hiCD105hi Phenotype within CD235a- Early Erythroid Progenitors. Stem Cells. 2025, September 16. Impact factor: 6.277

Chatenoud H, Łaniewski P, Mahnert ND, Herbst-Kralovetz MM. Metabolic comparison of minimally to noninvasive urogenital sample types for studying gynecologic health: A pilot study. iScience. 2025 June, 18. Impact factor: 6.107

McDougal LM, Baker FL, Gustafson MP, Katsanis E, Simpson RJ. Exercise-mobilized donor lymphocyte infusions (DLI-X) enhanced with cytokine stimulation (DLI-XS) for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation. Frontiers in Immunology. 2025, June 12. Impact factor: 5.9

Baker FL, SJ, Cracchiolo MJ, Davini D, Simpson RJ., Katsanis E. Impact of post-transplant cyclophosphamide with bendamustine on immune reconstitution in young patients undergoing T-cell replete haploidentical bone marrow transplantation: results from a phase Ia/Ib clinical trial. Frontiers in Immunology. 2025, April 8. Impact factor: 5.9

Lee EJ, Edgerton ML, Buccilli B, Telkes I, Harland T, Pilitsis JG. Prediction of Response to Spinal Cord Stimulation Using Machine Learning Based on Radiomics and Patient-Reported Outcomes. Neurosurgery. 2025, August 29. Impact factor: 5.315

Wright EB, Larsen EG, Padilla-Rodriguez M, Langlais PR, Bhattacharya MRC. TMEM184B modulates endolysosomal acidification via the vesicular proton pump. J Cell Sci. 2025, August 8. Impact factor: 5.235

Barker K, Marco T, Husnain M, Katsanis E. Addition of Phosphorous and IL6 to m-EASIX Score Improves Detection of ICANS and CRS, as Well as CRS Progression. Cancers. 2025, June 3. Impact factor: 5.2

Petrik AF, Badicke B, Davis MM, Miech EJ, Coury J, Kenzie ES, Schneider JL, Durr R, Edelmann AC, Herreid-O'Neill A, Myers E, Coronado GD. Difference-making factors for successful implementation of a multicomponent colorectal cancer screening program in rural clinics (SMARTER CRC). Front Med (Lausanne). 2025, June 25. Impact factor: 5.058

Lothrop N, Gutenkunst S, Fimbres J, Quijada C, Chaires M, Cortez I, Sandoval F, Camargo FJ, Rami­rez DM, Gallardo EV, Torabzadeh E, Wagoner R, Lopez-Galvez N, Ingram M, Carvajal S, Billheimer D, Wolf AM, Beamer PI. Characterizing full-shift worker exposures to VOCs in small-sized auto repair shops in the Tucson, Arizona, USA metropolitan area. Sci Rep. 2025, July 1. Impact factor: 4.996

Brown HE, Pauli L, Dholakia R, Gunderson J, Jernberg J, Sanderson PR, Harris RB, Monroy FP. Helicobacter pylori Diagnostic Testing Accuracy in a High-Prevalence Native American Population of Northern Arizona. Microorganisms. 2025, August 18. Impact factor: 4.926

Conrad H,  Elkamel A,  Maltagliati A, Wang K,  Hsu CH,  Linville W,  Lada M,  Sridhar P,  Worrell S. Outcomes of jejunostomy-tube placement in surgical patients with esophageal cancer. JTCVS Open. 2025, January 20. Impact factor: 4.9

Filioglou D, Leite GSF, Batatinha H, Santa-Cruz N, Davini DW, Baker FL, Simpson RJ, Katsanis E. Cytokine-induced memory-like NK cells combined with Tafasitamab demonstrate efficacy against B-cell acute lymphoblastic leukemia. Immunother Adv. 2025, July 16. Impact Factor: 4.9

Filioglou D, Leite GSF, Batatinha H, Santa-Cruz N, Davini DW, Baker FL, Simpson RJ, Katsanis E. Cytokine-induced memory-like NK cells combined with Tafasitamab demonstrate efficacy against B-cell acute lymphoblastic leukemia. Immunother Adv. 2025, July 16. Impact factor: 4.9

Daw J, Chung S, Chen CY, Heimark RL, Montfort WR. Real-Time Nitric Oxide Detection in Cytokine Stimulated Cancer Cells and Macrophages. Nitric Oxide. 2025, February 28. Impact factor: 4.4

Batatinha H, Peña NA, Hoskin GA, Kistner TM, Diak DM, Niemiro GM, Katsanis E, Simpson RJ. Exercise Delays Human Leukemia Progression and Mitigates Graft-Versus-Host Disease After Donor Lymphocyte Infusion in Xenogeneic Mice. Cancers. 2025, August 29. Impact Factor: 4.4

Filioglou D, Kovacs K, Lafleur BJ, White LM, Katsanis E. Haploidentical vs. Matched Sibling Donor HCT in Racially Diverse Pediatric and AYA Patients with Hematologic Malignancies: A Single-Center Comparison. Transplant Cell Ther. 2025 Sep 8. Impact Factor: 4.4

Ziller SG, Blew RM, Roe DJ, Odegaard A, Chen Z, Caan BJ, Luo J, Manson JE, Neuhouser ML, Rohan TE, Bea JW. Dual-energy X-ray absorptiometry derived adiposity and colorectal cancer incidence and mortality in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2025, August 1. Impact factor: 4.254

Allen AM, Cao Q, Stayer LG, Luo X, Jensen J, Pang RD, Allen S, Donny EC, Benowitz N, Smith T,  Hatsukami D. Differences in Combustible Cigarette Smoking-Related Biomarkers by Hormonal Contraceptive Use: An Exploratory Study. Nicotine Tob Res. 2025, January 30. Impact factor: 4.2

Gautam NJ, Jimenez NR, Łaniewski P, Cui H, Roe DJ, Chase DM, Herbst-Kralovetz MM. Microbiome impacts quality of life in patients with endometrial cancer and benign gynecological conditions. Qual Life Res. 2025, July 19. Impact factor: 4.147

Martinez-Guerrero LJ, Vignaux PA, Farrera DO, Harris JS, Raman R, Lane TR, Wright SH, Ekins S, Cherrington NJ. Experimental and computational approaches for evaluating molecule interactions with equilibrative nucleoside transporters 1 and 2. J Pharmacol Exp Ther. Published online July 15, 2025. Impact factor: 4.03

Rocha AD, Long DJ, Drake WK, Galvez DB, Rice PF, Reed MN, Heusinkveld JM, Barton JK.  First Clinical Feasibility and Safety Study of a Novel Multimodality Fallopian Tube Imaging Endoscope. Lasers Surg Med. 2025, February 1. Impact factor: 4.0

Alsowaida YS, Alsolami A, Almangour TA, Abraham I. Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA Adverse Events Reporting System (FAERS). Expert Opin Drug Saf. 2025, February 1. Impact factor: 4.0

Kaur J, Brooks HW, Froemming MN, Cusick NC, Funk JL, Farr JN. Examination of Skeletal and Senescence Phenotypes in Young Mice with Juvenile Onset Type 1 Diabetes. Calcif Tissue Int. 2025, July 1. Impact factor: 4.0

Harel K, Czamanski-Cohen J, Cohen M, Caspi O, Weihs KL. Coping, Emotional Processing, and Cancer-Related Symptoms in Breast Cancer Survivors: Cross-Sectional Secondary Analysis of the REPAT Study. Psychooncology. 2025, February 1. Impact factor: 3.9

Pontifex T, Yang X, Tracy A, Craig Z, Zhou C. Prenatal Exposure to Environmentally Relevant Low Dosage Dibutyl Phthalate Reduces Placental Efficiency in CD-1 Mice. Toxicol Sci.  2025, July 1; Impact factor: 3.8

Sharma A, Secomb TW. A theoretical model for oxygen transport to the cerebral cortex: effects of flow redistribution by penetrating arterioles. Microvasc Res. 2025, September. Impact factor: 3.75

Toner B, Arberet S, Zhang S, Han F, Ahanonu E, Goerke U, Johnson K, Abouelfetouh Z, Codreanu I, Sridhar S, Arif-Tiwari H, Deshpande V, Martin DR, Nadar M, Altbach MI, Bilgin A. Accelerated free-breathing abdominal T2 mapping with deep learning reconstruction of radial turbo spin-echo data. Magn Reson Med. 2025, August 5. Impact factor: 3.737

Rivelli JS, Schneider JL, Vaughn KA, Locher BW, Shaw MC, Martinez LS, Ruiz E, Thompson JH, Escaron AL, Coronado GD. Improving animated instructional videos for colorectal cancer screening: An application of learner verification and revision. Transl Behav Med. 2025, January 16. Impact factor: 3.626

Goodrich JM, Furlong MA, Urwin DJ, Gabriel J, Hughes J, Jung AM, Calkins MM, DuBose KN, Caban-Martinez AJ, Solle NS, Beitel SC, Burgess JL. Epigenetic Modifications Associated With Wildland-Urban Interface (WUI) Firefighting. Environ Mol Mutagen. 2025, January 1. Impact factor: 3.6 

Fox RS, Brandon K, Badger TA, Gaumond JS, Morales AA, Ong JC, Parthasarathy S, Rini C, Zee PC,  Tanner EJ, Ancoli-Israel S, Penedo FJ, Siddique J,  Wu LM,  Reid KJ, Kaiser K. Stakeholder-informed  refinement of a behavioral sleep/circadian intervention for gynecologic cancer survivors: an application of the MOST preparation phase. Transl Behav Med. 2025, January 16. Impact factor: 3.6

Sunny SP, Chen J, Wang Y, Paulmajumder B, Song B, Subhashini AR, Pillai V, Kuriakose MA, Birur N P, Suresh A, Liang R. Label-free deep UV microscopy in oral cytology: a step towards stain-free diagnostics. Biomed Opt Express. 2025, July 28. Impact factor: 3.562

Lima N,  DeLeon CM,  Sawyer TW. Polarimetry through a flexible imaging fiber bundle with a pixelated polarizer. Biomed Opt Express. 2025, April 1. Impact factor: 3.5

Galouzis N, Khawam M, Alexander EV, Mesropyan L, Luu C, Khreiss MR, Riall TS. Quality of Life and Social Health in Patients After Pancreatic Surgery. J Gastrointest Surg. 2025,  March 1. Impact factor: 3.5

Hart LJ, Barker K, Ruzdija D, Bertolo A, Paster IC, Estrada-Mendizabal RJ, Guillen JM, Recio-Boiles A, Chipollini J. Tumor profiling of advanced urothelial carcinoma: Comparative analysis based on social determinants of health. Urol Oncol. 2025, July 8. Impact factor: 3.498

Bea JW, Ochs-Balcom HM, Valencia CI, Chen Z, Blew RM, Lind KE, Caan BJ, Roe DJ, Rohan TE, Reeves KW,  Manson JE, Ballinger T, Reding KW,  Follis S, Ziller SG, Odegaard AO. Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidence. JNCI Cancer Spectr. 2025, January 3. Impact factor: 3.4

Young S, Zarama D, DSouza D, Golzarian J, Anderson JK. Comparison of the safety and effectiveness of cryoablation for T1 renal cell carcinoma in organ or tissue transplant recipients as compared to non-transplant patients. Abdom Radiol (NY).  2025, June 12. Impact factor: 3.0

Marcarian HQ, Sivakoses A, Arias AM, Ihedioha OC, Lee BR, Bishop MC, et al. Renal cancer cells acquire immune surface protein through trogocytosis and horizontal gene transfer.  PLoS One. 2025, May 5. Impact factor: 3.2

Brar G, Shroff RT. Anti-PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time? J Immunother Precis Oncol. 2025, May 12. Impact factor: 3.2

Sivakoses A, Marcarian HQ, Arias AM, Lam AR, Ihedioha OC, Santamaria-Barria JA, Gurtner GC, Bothwell ALM. Triple negative breast cancer cells acquire lymphocyte proteins and genomic DNA during trogocytosis with T cells. PeerJ. 2025, March 31. Impact factor: 3.06

Fussell JB, Shaw JP, Grams MA, Sung YS, Jheng RH, Astashkin AV, Tomat E. Disulfide-based 2-pyridyl-hydrazone prochelators induce iron deprivation and oxidative stress in ovarian cancer cells. J Biol Inorg Chem. 2025, July 1. Impact factor: 3.0

Aromokeye R, Ackerman-Berrier M, Araujo RDC, Lambousis M, Cardoza S, Chen L, Kaplan ME, Zhu H,  Zerbinatti C, Penton C, Thatcher GRJ,  Marlowe T. Development of a high-throughput TR-FRET assay to identify inhibitors of the FAK-paxillin protein-protein interaction. SLAS Discov. 2025, May 1. Impact factor: 2.9

Harel K, Czamanski-Cohen J, Cohen M, Lane RD, Allen JJB, Caspi O, Weihs KL. Cardiac Vagal Control and Emotional Awareness Associated With Pain Among Breast Cancer Survivors. Psychophysiology. 2025, June 1. Impact factor: 2.9

Armin JS, Goodie JL, Steiner M, Seehusen DA, Miller NE. How Team Science Is Documented and Described in Published Family Medicine Research. J Am Board Fam Med. 2025, September 15. Impact factor: 2.657

Segrin C, Sikorskii A, Cunicelli N, Badger T. Moderators of interdependent psychological distress in cancer survivor-caregiver dyads. J Psychosoc Oncol. 2025, January 9. Impact factor: 2.6

Stern D, Gomez-Flores-Ramos L, Trabert B, Setiawan, WR, Le Marchand L, Gomez H, Scheet PA, Parada H Hr, Pirzada A, Lajous M, Farland LV. Leveraging existing cohort studies of Mexican women to better understand Hispanic health and cancer risk. Cancer Causes Control. 2025, April 17. Impact factor: 2.506

Palmer KNB, Mantina NM, Adegboyega A, Sokale IO, Pryor K, Suero-Davis A, Brooks T, Hatcher J. Group concept mapping to develop a salon-based HPV self-collection intervention. Cancer Causes Control. 2025, August 27. Impact factor: 2.506

Maldonado A, Loya JC, Villavicencio EA, Torres R, Sanchez E, Luzanilla E, Garcia T, Vazquez L, Hoffman RM, Torres E, Garcia DO. Understanding Drivers of Prostate Cancer Screening in Mexican-Origin Men Along the U.S./Mexico Border Region. Am J Mens Health. 2025, June 23. Impact factor: 2.403

Coronado GD, Dickerson JF, Petrik AF, Arredondo E, Tsou MH, Martinez LS, Jenkins CL, Rosales AG, Shivaprakash N, Shuster E, Schneider JL, Rivelli JS, Garcia JG, Perez JA, Mendoza K, Thompson JH, Escaron AL. Community-clinic partnership to address social needs and improve colorectal cancer screening outcomes: The PRIME stepped-wedge study. Contemp Clin Trials. 2025, August 20. Impact factor: 2.261

Thompson J, Gautom P, Rivelli J, Johnson C, Burns M, Levell C, Hayes N, Coronado G. Faith-based Messaging and Materials for Colorectal Cancer Screening in the United States: Application of Boot Camp Translation within the African Methodist Episcopal Church. J Relig Health. 2024, November 24. Impact factor: 2.0

Battan-Wraith S, Elkamel A, Wang K, Alexander E, Harris TR, Hsu CH, Rice J, Sridhar P, Worrell SG. Outcomes of Minimally Invasive Versus Open Esophagectomy. J Surg Res. August 19, 2025. Impact factor: 2.192

Morenz AM, Nichols J, Snyder A, Perkins J, Prince DK, Ganzarski O, Hussein Z, Kim NJ, Dick A, Ng YH. Exploring Caregiver Support as a Potential Mediator of Neighborhood Socioeconomic Disadvantage and Reduced Likelihood of Liver Transplant Waitlisting. Transplant Direct. 2025, March 28. Impact factor: 1.9

Warner EL, Traslavina Jimenez J, Sikorskii A, Segrin C, Crane T, Badger TA. Feedback on Adapting Interventions for AYA Cancer Survivors' and Caregivers' Psychological Distress, Symptom Management, and Health Care Use. J Adolesc Young Adult Oncol. August 18, 2025. Impact factor: 1.757

Segrin C, Sikorskii A, Cunicelli N, Badger T. Moderators of interdependent psychological distress in cancer survivor-caregiver dyads. J Psychosoc Oncol. 2025, January 9. Impact factor: 1.5

Nicholas T, Hamann HA, Price, SN, & Weihs K. Coping strategies and changes in depressive symptoms: Insights from a collaborative care intervention for individuals facing cancer in underserved communities. J Psychosoc Oncol. , 2025, August 12. Impact factor: 1.5

Tseng HW, Fu Z, Vedantham S. Simultaneous Reduction of Radiation Dose and Scatter-to-Primary Ratio using a Truncated Detector and Advanced Algorithms for Dedicated Cone-Beam Breast CT. Biomed Phys Eng Express. 2025, March 3. Impact factor: 1.3

Maggert K, Kindelay S. The Drosophila FM7 - A Strain Contains a Fixed Translocation Involving the X and 4 Chromosomes. MicroPubl Biol. 2025. Impact factor: None.

Zhu YX, Dutta S, Ahmann GJ, Bruins L, Arribas M, Chen X, Polavarapu A, Chapman J, Lopez I, Chesi M, Bergsagel PL, Singharoy A, Fonseca R, Rimsza LM. A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma. Blood Neoplasia. 2025, April 4. Impact factor: None

Chauhan SS, Vizzerra AD, Liou H, Flores CE, Snider AJ, Snider JM, Warfel NA. Hypoxia induced lipid droplet accumulation promotes resistance to ferroptosis in prostate cancer. Oncotarget. 2025, June 25. Impact factor: None

Collaborators

List of cancer center members and associates who were listed on a publication, but were not first, last or corresponding author. 

Aragaki AK, Manson JE, LeBlanc ES, Chlebowski RT, Tinker LF, Allison MA, Haring B, Odegaard AO, Wassertheil-Smoller S, Saquib N, Masaki K, Harris HR, Jager LR, Bea JW, Wactawski-Wende J, Anderson GL. Development and Validation of Body Mass Index-Specific Waist Circumference Thresholds in Postmenopausal Women : A Prospective Cohort Study. Ann Intern Med. 2025, July 8. Impact factor: 51.598

Damiani T, Jarmusch AK ... Marty MT ... Wang M. A universal language for finding mass spectrometry data patterns. Nat Methods. 2025, May 12; Impact factor: 47.99

Ligibel JA, Ballman KV, McCall L, Goodwin PJ, Alfano CM, Bernstein V, Crane TE, Delahanty LM, Frank E, Hahn O, Hershman DL, Hopkins JO, Irwin M, Mayer EL, Minasian L, Nebeling L, Neuhouser ML, Paskett ED, Spears PA, Stearns V, Thomson CA, Weiss A, White J, Wadden TA, Winer EP, Hudis C, Partridge AH, Carey LA. Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial. JAMA Oncol. 2025, August 21. Impact factor: 33.006

Knox JJ,  McNamara MG,  Bazin IS, Oh DY,  Zubkov O, Breder V, Bai LY, Christie A, Goyal L, Cosgrove DP, Springfeld C, Sjoquist KM,  Oh Park J, Verdaguer H, Braconi C, Ross PJ, De Gramont A, Shroff RT, Zalcberg JR, Palmer DH, Smith JR, Oelmann E,  Bruce T, Valle JW. A phase III randomised study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer. J Hepatol. 2025, February 18; Impact factor: 30

Buchanan C, Karunanithy G, Tkachenko O, Barber M, Marty MT, Nott TJ, Redfield C,  Baldwin AJ. Unidec NMR: automatic peak detection for NMR spectra in 1-4 dimensions. Nat Commun. 2025, January 7. Impact factor: 17.7

Palczewski MB, Kuschman HP, Hoffman BM, Kathiresan V, Yang H, Glynn SA, Wilson DL, Kool ET, Montfort WR, Chang J, Petenkaya A, Chronis C, Cundari TR, Sappa S, Islam K, McVicar DW, Fan Y, Chen Q, Meerzaman D, Sierk M, Thomas DD. Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome. Nat Commun. 2025, February 18. Impact factor: 17.7

Martin L, Stratton HJ, Salih LY, Dumaire N, Gomez K, Do LD, Loya-Lopez S, Tang C, Calderon-Rivera A, Ran D, Nunna V, Bellampalli SS, Francois-Moutal L, Luo S, Porreca F, Ibrahim M, Rogemond V, Honnorat J, Khanna R, Moutal A. Anti-CV2/CRMP5 autoantibodies as drivers of sensory neuron excitability and pain in rats. Nat Commun. 2025, Aug 7. Impact factor: 17.694

Roland-McGowan JN, Freeman SC, Baghoomian W, Carroll BT, Kim CC, Curiel-Lewandrowski C, Chu EY,  Foster EL,  Nelson KC, White KP,  Ming ME,  Hartman RI, Leachman SA, Mengden-Koon S, Chen SC, Swetter SM, Prieto VG,  Berry E, Yu WY. Development of a Treatment Decision Aid for Patients with Dysplastic Nevi Who Are Candidates for Re-Excision. J Am Acad Dermatol. 2025, January 7; Impact factor: 15.5

Nascimento De Lima P, Bartholomew L, May FP, Coronado GD, Rutter CM. The triple-effect of colorectal cancer screening: reducing deaths, government spending and mortality disparities. J Natl Cancer Inst. Published online 2025, July 30. Impact factor: 13.506

Compton SLE, Wopat H, Lopez-Pentecost M, Agurs-Collins T, Brown JC, Caan B, Demark-Wahnefried W, Elena JW, Ferrucci LM, McGowan C, Puklin LS, Schmitz KH, Thomson CA, Robien K, Crane TE, ENICTO Consortium. Addressing conceptual and design gaps in the oncology nutrition evidence base during chemotherapy: contributions of the Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes Consortium. J Natl Cancer Inst. 2025, July 18. Impact factor: 13.506

Nascimento de Lima P, Matrajt L, Coronado G,  Escaron AL, Rutter CM. Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics. JAMA Netw Open. 2025, January 1. Impact factor: 13.3

Mesgarzadeh S, Amamoo RS, Ameneni G, Gong AH, Ayoade OO, Stratton DB, Latour E, Yu W, Curiel-Lewandrowski C, Abraham I, Fazel M. Validation of risk prediction models for sentinel lymph node metastasis in melanoma in a high UV index region. JAAD Int. 2025, June 6. Impact factor: 12.8

Ardalan B, Ciner A, Baca Y, Hinton A, Darabi S, Kasi A, Lou E, Azqueta JI, Xiu J, Datta J,  Shields AF, Aguirre A, Singh H, Shroff RT, Pishvaian MJ, Goel S. Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma. Clin Cancer Res. 2025, March 17;. Impact factor: 12.5

Naudin S,  Wang M,  Dimou N,  Ebrahimi E, Sawada N,  Schoemaker M,  Shu XO,  Sinha R,  Snetselaar L,  Stampfer MJ,  Stolzenberg-Solomon R,  Thomson CA, Ferrari P. Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America. PLoS Med. 2025, May 20. Impact factor: 11.6

Nguyen HTX, Kim BG, Myers JT,  Yan H,  Kumar S, Eid S,  Wang W, Huang AY, Liang FS. Engineering TME-gated inducible CAR-T cell therapy for solid tumors. Mol Ther. 2025, April 30; Impact factor: 11.4

Marroquin JM, Krall JR, Schliep K, Farland LV, Krishnamoorthi V, Kannan K, Pollack AZ. Per- and polyfluoroalkyl substances in eutopic endometrium tissue and risk of endometriosis: findings from the Investigating Mixtures of Pollutants and Endometriosis in Tissue (IMPLANT) Study. Environ Health Perspect. 2025, June 1. Impact factor: 11.3

Danilov AV, Li H, Shadman M, Rimsza L, Zebari A, Smith SM, LeBlanc M, Friedberg JW, Carlson C, Song JY. Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial. Haematologica. 2025, July 3. Impact factor: 11.047

Zhang Y, Shi H, Wang Y, Liu W, Li G, Li D, Wu W, Wu Y, Zhang Z, Ji Y, Zhu C, Bai W, Lei H, Xu H, Zhong H, Han B, Yang L, Liu L, Wang W, Zhao Y, Zhang Y, Wu Y. Noscapine derivative 428 suppresses ferroptosis through targeting GPX4. Redox Biol. 2025, April 12. Impact factor: 10.7

Hossain NM, Ahn KW, Patel J, Lian Q, Abid B, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF. Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS. Br J Haematol. 2025, July 22. Impact factor: 8.615

Wang Q, Roh E, Khan AU, Dickinson S, Wondrak GT, Bode AM, Curiel-Lewandrowski C, Zhang T. Deletion of p53-Related Protein Kinase Suppresses Solar UV-Induced Photocarcinogenesis by Inhibiting PD-L1 Expression and Enhancing CD8 T-Cell Infiltration. J Invest Dermatol. Published online August 12, 2025. Impact factor: 8.551

Ng J, Diehl K, Petrie T, Tobey T, Stoos E, Latour E, Ludzik J, Orfaly VE, Nelson J, Gillespie J, Foltz EA, Berry EG, Verdieck A, Curiel-Lewandrowski CN, Nelson KC, Smith EH, Swetter SM, Leachman S. The Melanoma Toolkit for Early Detection Improves Accuracy but Fails to Improve the Number Needed to Biopsy. J Invest Dermatol. 2025, July 17. Impact factor: 8.551

Ng JW, Diehl KL, Petrie TC, Tobey TN, Stoos ER, Latour EJ, Ludzik JN, Orfaly VE, Nelson JH, Gillespie JR, Foltz EA, Berry EG, Verdieck A, Curiel-Lewandrowski C, Nelson KC, Smith EH, Swetter SM, Leachman SA. The Human Factor: Unpacking Biopsy Decision Variability That AI Can't Predict. J Invest Dermatol. 2025, August 21. Impact factor: 8.551

Hogan DE, Dardona M, Graves K, Tummala CM, Praneeth S, Boxley C, Maier RM, Dittrich TM. Evaluation of glycolipid functionalized organosilica media for adsorption of rare earth elements and uranium. J Environ Manage. 2025, July 15. Impact factor: 8.4

Juetten KJ, Sanders JD, Marty MT, Brodbelt JS. Combining Fourier Transform Ion Mobility with Charge Detection Mass Spectrometry for the Analysis of Multimeric Protein Complexes. Anal Chem. 2025, January 14. Impact factor: 8.0

Wu LW, Deshmukh SK, Wu S, Xiu J, Jang SJ, Park J, Lam VK, Lou E, Goel S. Shroff RT, Moy RH. Multi-omic characterization of early-onset esophagogastric cancer. NPJ Precis Oncol. Published 2025 Jul 17. Impact factor: 8.0

Sisoudiya SD, Tukachinsky H, Keller-Evans RB, Schrock AB, Huang RSP, Gjoerup O, Pishvaian MJ, Shroff R, Sokol ES, Dennis L, Frampton GM, Sivakumar S. Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction. NPJ Precis Oncol. 2025, June 17. Impact factor: 8.0

Collinge BJ, Hilton LK, Wong JCH, Alduaij W, Ben-Neriah S, Slack GW, Farinha P, Boyle M, Meissner B, Cook JR, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami GG, Ondrejka SL, Jaffe ES, Weisenburger DD, Chan WC, Holte H, Beiske K, Fu K, Delabie J, Pittaluga S, Iqbal J, Wright G, Savage KJ, Mungall AJ, Staudt LM, Steidl C, Feldman AL, Morin RD, Rimsza LM, Scott DW. High-grade B-cell lymphoma, not otherwise specified: an LLMPP study. Blood Adv. 2025, July 17, 2025. Impact factor: 7.637

Ramsower CA, Wright G, Li H, Cerhan JR, Maurer MJ, Mwangi R, Rosenthal AC, Novak AJ, Link BK, Witzig TE, Habermann TM, Kridel R, LeBlanc ML, Shadman M, Smith SM, Friedberg JW, Scott DW, Steidl C, Staudt LM, Rimsza LM. Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma. Blood Adv. 2025, September 18. Impact factor: 7.637

Gutmair K, Villa D, Cunningham N, Silkenstedt E,  Rimsza LM,  Ramsower CA, Scott DW, Gerrie AS, Kluin-Nelemans HC, Dreyling M, Hoster E. BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma. Blood Adv. 2025, February 21;. Impact factor: 7.6

Cui J, Mukherjee A, Patel PG, Junkins A, Agarwal G, Giri S, Griffin R, Sudenga SL, Shrestha S. Sex and organ-specific risk and temporal trends of human papillomavirus-associated anogenital cancer among solid organ transplant recipients in the United States. Int J Cancer. 2025, September 16. Impact factor: 7.316

Li D, Shen S,  Liu C,  Guo T,  Liu Y,  Pan P,  Zhao X,  Ma Y,  Li L,  Huang S,  Shen W,  YoupingZhang,  Jiang B,  Wang W,  Yin Q,  Zhang Y. Discovery of novel and highly potent anticancer agents enabled by selenium scanning of noscapine. Eur J Med Chem. 2025, April 30. Impact factor: 7.0

Studts JL, Carter-Bawa L, Hamann HA, Smith RA, Kazerooni EA, Rosenthal LS, Stigma and Nihilism Task Group of the American Cancer Society National Lung Cancer Roundtable. The American Cancer Society National Lung Cancer Roundtable strategic plan: Changing the lung cancer story: Addressing survivorship, stigma, and nihilism to facilitate transformation. Cancer. 2025, August 15. Impact factor: 6.921

Marcotte LM,  Khor S,  Reddy A,   Morenz A,  Nelson K,  Akinsoto N, Lee ES,  Onstad S, Wong ES. An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system. Cancer. 2025, February 1. Impact factor: 6.9

Stimpson JP, Liao JM, Morenz AM, Joo JH, Wilson FA. A difference-in-differences analysis of Medicaid expansion and state paid sick leave laws on colorectal cancer screening. Cancer. 2025, May 15. Impact factor: 6.9

Khan AU, Wang Q, Roh E, Dickinson SE, Wondrak GT, Curiel-Lewandowski C, Bode AM, Zhang T. TOPK Drives IL19-Mediated Crosstalk Between Cancer Cells and Fibroblasts to Promote Solar UV-Induced Skin Damage and Carcinogenesis. Cancers (Basel). 2025, June 20. Impact factor: 6.575

Abdelrahim M, Esmail A, Kim RD, Arora SP, Arshad J, Kournoutas IA, ODonnell CD, Totev TI, Tan A, Mu F, Seshasayee SM, Hernandez S, Tran NH. Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study. Cancers (Basel). 2025, May 2. Impact factor:  6.5

Dommer J, Van Doorslaer K, Afrasiabi C, Browne K, Ezeji S, Kim L, Dolan M, McBride AA. PaVE 2.0: Behind the Scenes of the Papillomavirus Episteme. J Mol Biol. 2025, August 1. Impact factor: 6.1

Ma J, Liu W, Li J, Kim D, Kim S, Levy A, Cai Z, Bunker KD, Recio-Boiles A, Segar JM, Sen S, Doroshow DB, Jandial D, Rutgard M, Harismendy O, Grant SK, Samatar AA, Fischer KM, Lackner MR. Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumors. Mol Cancer Ther. 2025, August 1. Impact factor: 6.009

Shi Y, Hsu CC, Robbins JR. Clinical outcomes for unresectable anaplastic thyroid cancer treated with radiation: Impacts of radiation intent and the percentage of life spent receiving treatment. Oral Oncol. 2025, June 25. Impact factor: 5.972

Chung V, Alistar A, Becerra C, Kasi A, Borazanci E,  Jameson GS, Roe DJ, Wertheim BC,  Cridebring D, Truitt M, Downes M,  Barrett MT, Korn R,  Lee K, Han H, Evans R, Von Hoff DD. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Oncologist. 2025, January 17. Impact factor: 5.8

Cohen DJ, Goldberg JD, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott AJ, Bekaii-Saab T, Messersmith WA, Weekes CD. Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma: An Academic Gastrointestinal Cancer Consortium (AGICC) Study. Oncologist. 2025, September 16. Impact factor: 5.8

Frisbey AA, Nash TE, Goshe MB, Clouse SD, Frost CJ, Tax FE. CEPR1 regulates Arabidopsis thaliana root architecture by modulating auxin production via NIT1. Plant J. 2025, July. Impact factor: 5.7

Tan Y, Wang W, Xu L, Zhou X, Shen J, Zhou T, Duan C, Wang X, Liu Z, Wang M, Li G. Decellularized human amniotic member hydrogel promotes limbal stem cells proliferation. Colloids Surf B Biointerfaces. 2025, August . Impact factor: 5.4

Molena D, Sewell M, Maron SB, Hofstetter W, Worrell S, Chen KN, Enzinger PC, Gerdes H, Kleinberg L, Murthy S, Palta M, Pouw RE, Reddy RM, Sanford DE, Schumacher L, Sihag S, Berry MF. The 2025 American Association for Thoracic Surgery (AATS) expert consensus document: Surgical management of esophageal and gastroesophageal junction cancer. J Thorac Cardiovasc Surg. 2025, May 4. Impact factor: 5.209

Chen J,  Trindl CA,  Ye H,  Huang D,  Ooi A,  Garcia JGN,  Chapman E,  Zhang DD. CYP4F11, an NRF2 Target Gene, Promotes Hepatocellular Carcinoma Cell Growth. Mol Carcinog. 2025, May 6; Impact factor: 5.1

Fest SN, Farland LV, Doody DR, Eliassen AH, Rosner BA, Fung TT, Hankinson SE, Kensler TW, Willett WC, Harris HR. Hormone-associated dietary patterns and premenopausal breast cancer risk. Breast Cancer Res Treat. 2025, July 1. Impact factor: 4.6

Gemmill JAL, Thompson P, Batiste R, Vacchi-Suzzi C, Preece C, Cohen J, Baer L, Mies C, Turner M, Russell CA, Stopeck A. Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study. Breast Cancer Res Treat. 2025, May 28; Impact factor: 4.6

Deressa BT, Pierz A, Jyung H, Rosario B, Andoh-B-Baidoo N, Tibebu B,  Seife E, Bekele E, Hussein R,  Gedif T, Madhivanan P, Lott B. A qualitative study on the psycho-oncological experiences of women navigating breast cancer diagnosis, treatment, and survivorship in Ethiopia. J Cancer Surviv. 2025, February 8; Impact factor: 4.4

Wallace R, Smith I, Day D, Alexander M, Weihs KL, Wiley JF. A randomized controlled trial: Evaluating whether a cognitive behavioral internet-delivered intervention targeting emotion regulation improves health-related quality of life in cancer survivors. Health Psychol. 2025, April 10. Impact factor: 4.267

Lin N, Vitonis AF, Mongiovi JM, Farland LV, Huang T, Terry KL, Eliassen AH, Townsend MK, Zhang C, Hu FB, Sasamoto N. History of Breastfeeding in Relation to Circulating Inflammatory and Metabolic Biomarkers. Cancer Epidemiol Biomarkers Prev. 2025, September 2. Impact factor: 4.254

Nash SH, Loeffler BT, Verhage E, Sorensen J, Slater VE, Elenwa F, Erdrich J, Livermont T, Sanderson PR, Blackwater C, Smith BJ, Ulmer KK, McDowell BD. Comorbidities among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results (SEER)-Medicare Study. Cancer Epidemiol Biomarkers Prev. 2025, September 9. Impact factor: 4.254

DeVito EE, Allen AM, Weinberger AH. Nicotine and Tobacco Research Related to Sex/Gender: A 10-Year Update. Nicotine Tob Res. 2025, July 29. Impact factor: 4.244

Zhao YJ, Zhang SY, Wei YY,  Li HH,  Lei W, Wang K, Kumar S, Zhou C, Zheng J. An Endogenous Aryl Hydrocarbon Receptor Ligand Dysregulates Endothelial Functions, Transcriptome, and Phosphoproteome. Am J Physiol Cell Physiol. 2025, March 1. Impact factor: 4.2

Vergara-Lopez C, Papandonatos GD, Bublitz MH, Allen AM, Stroud LR. Electronic nicotine delivery systems (ENDS) use across the menstrual cycle and oral contraceptive regimen: A proof-of-concept intensive longitudinal study. Drug Alcohol Depend Rep. 2025, Jun 13. Impact factor: 4.2

Feng Y, Kupinski MA, Ottensmeyer MP, Worstell W, Tawakol A, Furenlid LR, Sabet H. Analytical methods for system matrix calculation and spatial resolution evaluation of DC-SPECT system. Phys Med Biol. 2025 Jul 18. Impact factor: 4.174

Stimpson JP, Tamirisa K, Morenz AM, Adhikari EH, Rodriguez Francis JK. Trust typologies and HPV awareness in the U.S.: a latent class analysis. Vaccine. 2025, August 12. Impact factor: 4.169

Segrin C, Badger TA, Cunicelli N, Sikorskii A. Effects of an Interpersonal Counseling Intervention on Interdependence of Symptoms in Cancer Survivor-Informal Caregiver Dyads. Psychooncology. 2025, August. Impact factor: 3.955

Weinfeld-Yehoudayan A, Czamanski-Cohen J, Weihs KL, Cohen M. Using Drawings to Measure Emotional Processing in Breast Cancer Survivors and Its Association With Depression, Pain, and Fatigue. Psychooncology. 2025, February 1. Impact factor: 3.9

Domanico MC, Collette NM, Ubick E, Ding X,  Buchholz BA, Van Winkle LS. DNA adducts form in mouse lung and liver after oral naphthalene exposure. Toxicol Sci. 2025, February 8. Impact factor: 3.8

Chen JY, Vedantham S, Lexa FJ. 3rd Comprehensive Survey of the Neuroradiology Work Environment in the United States with Reported Trends in Clinical Work, Nonclinical Work, Errors, Burnout and Retirement. AJNR Am J Neuroradiol. 2025, July 3. Impact factor: 3.7

Larkey LK, James DL, Han S, Weihs K, Jahnke R, Oh B, Kim SW, Huberty J, Petrov ME, Martin D, Howe N, Hook J, Soltero E, Rao S, Northfelt D. Randomized controlled trial testing Tai Chi Easy/Qigong and Sham Qigong on breast cancer survivors' fatigue and associated symptoms. Complement Ther Clin Pract. 2025, July 8, 2025. Impact factor: 3.577

Tamari N, Brown HE, Sedda L, Riehle MA, Ellingson KD, Walker KR, Christopherson GL, Atieli H, Munga S, Ernst KC. Structural features of outdoor latrines influence the abundance of Anopheles gambiae s.l. and Culex quinquefasciatus in a village in Kisumu County, western Kenya. Parasit Vectors. 2025, August 27. Impact factor: 3.5

Perez K,  Del Rivero J,  Kennedy EB,  Basu S,  Chauhan A,  Connolly HM,  Dasari AN,  Gangi A,  Clarke CN,  Hallet J,  Howe JR,  Grady E,  Ivanidze J,  Mittra ES,  White SB,  Raj NP,  Vijayvergia N,  Lewis MA,  Chan JA,  Kunz PL,  Mailman J,  Arshad J, Bergsland EK. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO Oncol Pract. 2025, May 9. Impact factor: 3.4

Hagio T, Galons JP,  Roe D, Marron MT, Thomson C, Thompson P, Stopeck AT, Bilgin A, Altbach MI, Chiang JA. Concurrent water T(2) and fat fraction mapping of the breast using the radial gradient and spin echo (RADGRASE) pulse sequence. Magn Reson Imaging. 2025,  February 1. Impact factor: 3.1

Superdock MA, Rimsza LM, Wallace DS, et al. Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study. Leuk Lymphoma. Published online 2025, August 6. Impact factor: 2.996

Bhandari A, Rogers SN, Vedantham S, et al. MRI evaluation of hyperostosis frontalis interna: differentiation and diagnostic insights. Neuroradiology. 2025, August 15. Impact factor: 2.995

Pete D, Farris PE, Adsul P, Bea JW, Decker D, Ingram J, Semprini J, Baker H, Yellowhair M, Blackwater C, Dee C, Briant KJ, Parker M, Zahnd WE, Nash SH. The inclusion of tribes and American Indian and Alaska Native People in State comprehensive cancer control plans. Cancer Causes Control. 2025, August. Impact factor: 2.506

Warner EL, Sikorskii A, Cunicelli N, Badger T, Segrin C, Morrill KE, Rainbow J. Employment productivity and cancer-related psychological symptoms among adult cancer dyads. J Occup Environ Med. 2025, January 30. Impact factor: 2.3

Wolter M, Reading JM, Solk P, Starikovsky J, Hasanaj K, Wang SD, Siddique J, Horowitz B, Spring B, Carden LB, Fox R, Sauer C, Freeman H, Frey J, Victorson D, Phillips SM. Optimizing a mHealth physical activity intervention with mindful awareness lessons in breast cancer survivors: Fit2ThriveMIND protocol. Contemp Clin Trials. 2025, July 31. Impact factor: 2.261

Schmitz KH, Berger NA, Owusu C, Thomson CA, Chinchilli VM, Basen-Engquist K, Evans WJ, Pink JJ, Schleicher EA, Cao C, Doerksen SE, Binder JD, Sobolewski MD, Tanasijevic AM, Diguglielmo KA, Nguyen TL, Mills CA, Kemp W, Oppenheim JB, Ligibel JA. TeleHealth resistance exercise intervention to preserve dose intensity and vitality in elder breast Cancer patients (THRIVE 65). Contemp Clin Trials. 2025, September 12. Impact factor: 2.261

Scholte LLS, Mello ES, Ibrahim KY, Uno M, da Costa VM, Miazima ES, Moniz CMV, de Souza GD, Amorim LO,de Souza IC, Oliveira K, Chammas R, Bowles K, Das L,Coghill AE, Rimsza L, Segurado A, Bethony JM. Advancing HIV and Cancer Research: Implementing an AIDS and Cancer Specimen Resource in Latin America. Biopreserv Biobank. Published online August 8, 2025. Impact factor: 2.256

Ko AH, Chao J, Noel MS, Shankaran V, Sohal D, Crow M, Oberstein PE, Scott AJ, McRee AJ, Rocha Lima CMSP,  Fong L, Keenan BP, Soto M, Filbert EL, Hsu FJ, Yang X. A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, Plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers. Cancer Res Commun. 2025, February 1. Impact factor: 2.0

Carson WO, Little A, Monetathchi A, Erdrich J, Cordova-Marks FM. Analysis of Urban Indian Organizations' Promotion of Cancer Services. Cancer Res Commun. 2025, February 1. Impact factor: 2.0

Su Y, Orchard TS, Shadyab AH, Skiba MB, Snetselaar L, Vitolins MZ, Richey PA, Coday M, Zaslavsky O. Mediterranean Diet and Change in Physical Function Over Time In Older Women. J Nutr Gerontol Geriatr. 2025, April-June. Impact factor: 1.3